President Donald Trump signed an executive order on Saturday directing the Food and Drug Administration (FDA) to expedite the review of certain psychedelic drugs, including ibogaine, for treating post-traumatic stress disorder (PTSD) and other mental health conditions. The order aims to accelerate access to research and potential treatments, particularly for veterans.
Core Facts
- Executive Order Signed: Trump’s directive expedites FDA reviews for psychedelics designated as breakthrough therapies, including ibogaine, a Schedule I controlled substance.
- Veteran Focus: The order highlights the potential of psychedelics to reduce depression and anxiety among veterans, citing a 2024 Stanford University study where 30 special operations veterans saw an 80-90% reduction in symptoms within one month.
Deeper Context
Policy and Research
The executive order follows bipartisan support for psychedelic research, with Health and Human Services Secretary Robert F. Kennedy Jr. and Veterans Affairs Secretary Doug Collins endorsing the move. Trump noted that the FDA will prioritize drugs already in advanced clinical trials, clearing bureaucratic hurdles to facilitate faster approvals. The order also includes a $50 million federal investment in ibogaine research, matching a similar commitment from Texas.
Controversy and Risks
Ibogaine, a naturally occurring psychedelic, remains a Schedule I drug due to its potential cardiac risks. Advocates argue its benefits for PTSD and opioid addiction outweigh these risks, but critics warn of its unregulated use. Trump joked about wanting to try the drug for anxiety, underscoring its polarizing nature.
Public and Political Reactions
Podcaster Joe Rogan, a vocal advocate for psychedelics, attended the signing. Veterans like former Navy SEAL Marcus Luttrell praised the move, calling it life-changing. However, some medical experts caution against premature approval without further safety data.
Long-Term Implications
The order could reshape mental health treatment for veterans, who face disproportionately high rates of PTSD and suicide. If successful, it may pave the way for broader psychedelic therapy access, though legal and safety challenges remain.